Flag of the European Union EU Clinical Trials Register Help

Clinical trials for eli lilly

The European Union Clinical Trials Register   allows you to search for protocol and results information on:
  • interventional clinical trials that were approved in the European Union (EU)/European Economic Area (EEA) under the Clinical Trials Directive 2001/20/EC
  • clinical trials conducted outside the EU/EEA that are linked to European paediatric-medicine development

    • EU/EEA interventional clinical trials approved under or transitioned to the Clinical Trial Regulation 536/2014 are publicly accessible through the
    Clinical Trials Information System (CTIS).

    The EU Clinical Trials Register currently displays   44394   clinical trials with a EudraCT protocol, of which   7406   are clinical trials conducted with subjects less than 18 years old.   The register also displays information on   18700   older paediatric trials (in scope of Article 45 of the Paediatric Regulation (EC) No 1901/2006).

    Phase 1 trials conducted solely on adults and that are not part of an agreed paediatric investigation plan (PIP) are not publicly available (see Frequently Asked Questions ).  
     
    Examples: Cancer AND drug name. Pneumonia AND sponsor name.
    How to search [pdf]
    Search Tips: Under advanced search you can use filters for Country, Age Group, Gender, Trial Phase, Trial Status, Date Range, Rare Diseases and Orphan Designation. For these items you should use the filters and not add them to your search terms in the text field.
    Advanced Search: Search tools
     
    1,061 result(s) found for: eli lilly. Displaying page 16 of 54.
    «« First « Previous 12  13  14  15  16  17  18  19  20  Next» Last»»
    EudraCT Number: 2011-005217-37 Sponsor Protocol Number: I4O-MC-BACC(b) Start Date*: 2012-08-22
    Sponsor Name:Eli Lilly and Company
    Full Title: Assessment of Safety, Tolerability, and Pharmacodynamic Effects of LY2886721 in Patients with Mild Cognitive Impairment Due to Alzheimer’s Disease or Mild Alzheimer's Disease
    Medical condition: Mild Cognitive Impairment Due to Alzheimer’s Disease or Mild Alzheimer's Disease
    Disease: Version SOC Term Classification Code Term Level
    14.1 100000004852 10001896 Alzheimer's disease LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: NL (Prematurely Ended) ES (Prematurely Ended) IT (Prematurely Ended)
    Trial results: View results
    EudraCT Number: 2013-001473-24 Sponsor Protocol Number: F3Z-MC-IOQL Start Date*: 2014-02-05
    Sponsor Name:Eli Lilly and Company
    Full Title: An Individualized treatMent aPproach for oldER patIents: A randomized, controlled stUdy in type 2 diabetes Mellitus
    Medical condition: Diabetes Mellitus, Type 2
    Disease: Version SOC Term Classification Code Term Level
    14.1 100000004861 10063624 Type II diabetes mellitus inadequate control LLT
    Population Age: Elderly Gender: Male, Female
    Trial protocol: GB (Prematurely Ended) DE (Prematurely Ended) AT (Prematurely Ended)
    Trial results: View results
    EudraCT Number: 2013-003552-21 Sponsor Protocol Number: I7I-MC-XNAA Start Date*: 2014-05-27
    Sponsor Name:Eli Lilly and Company
    Full Title: Comparison of the Oxyntomodulin Analog, LY2944876, to Once-Weekly Exenatide and to Placebo in Patients with Type 2 Diabetes.
    Medical condition: Diabetes Mellitus, Type 2
    Disease: Version SOC Term Classification Code Term Level
    16.1 100000004861 10045242 Type II diabetes mellitus LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: GR (Completed) PL (Completed) RO (Completed)
    Trial results: View results
    EudraCT Number: 2021-005273-47 Sponsor Protocol Number: I8F-MC-GPIG Start Date*: 2022-11-21
    Sponsor Name:Eli Lilly and Company
    Full Title: Tirzepatide Study of Renal Function in People with Overweight or Obesity and Chronic Kidney Disease with or without Type 2 Diabetes: Focus on Kidney Hypoxia in Relation to Fatty Kidney Disease usin...
    Medical condition: Obesity and Chronic Kidney disease
    Disease: Version SOC Term Classification Code Term Level
    20.0 10038359 - Renal and urinary disorders 10038359 Renal and urinary disorders SOC
    20.0 10027433 - Metabolism and nutrition disorders 10027433 Metabolism and nutrition disorders SOC
    Population Age: Adults Gender: Male, Female
    Trial protocol: NL (Trial now transitioned) DK (Trial now transitioned) AT (Trial now transitioned)
    Trial results: (No results available)
    EudraCT Number: 2020-000077-25 Sponsor Protocol Number: I5T-MC-AACI Start Date*: 2020-07-13
    Sponsor Name:Eli Lilly and Company
    Full Title: Assessment of Safety, Tolerability, and Efficacy of Donanemab in Early Symptomatic Alzheimer’s Disease
    Medical condition: Early Symptomatic Alzheimer’s Disease
    Disease: Version SOC Term Classification Code Term Level
    20.0 10029205 - Nervous system disorders 10012271 Dementia Alzheimer's type PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: PL (Trial now transitioned) NL (Trial now transitioned) CZ (Trial now transitioned)
    Trial results: View results
    EudraCT Number: 2019-002933-12 Sponsor Protocol Number: DRM06-AD05 Start Date*: 2020-10-12
    Sponsor Name:Dermira, a wholly owned subsidiary of Eli Lilly and Company
    Full Title: A RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED TRIAL TO EVALUATE THE EFFICACY AND SAFETY OF LEBRIKIZUMAB IN PATIENTS WITH MODERATE-TO-SEVERE ATOPIC DERMATITIS
    Medical condition: Atopic dermatitis
    Disease: Version SOC Term Classification Code Term Level
    21.1 100000004858 10003639 Atopic dermatitis LLT
    Population Age: Adolescents, Under 18, Adults, Elderly Gender: Male, Female
    Trial protocol: DE (Completed) BG (Completed) IT (Prematurely Ended)
    Trial results: View results
    EudraCT Number: 2007-005441-38 Sponsor Protocol Number: F1K-MC-EVDP Start Date*: 2008-03-07
    Sponsor Name:Eli Lilly and Company
    Full Title: Efficacy and Safety of Drotrecogin Alfa (Activated) in Adult Patients with Septic Shock
    Medical condition: Septic shock
    Disease: Version SOC Term Classification Code Term Level
    13.1 10021881 - Infections and infestations 10040070 Septic shock PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DE (Completed) GB (Completed) NL (Completed) FR (Completed) BE (Completed) IT (Completed) PT (Completed) FI (Completed) CZ (Completed) ES (Completed)
    Trial results: View results
    EudraCT Number: 2006-006315-68 Sponsor Protocol Number: B3D-EW-GHDH Start Date*: 2007-05-07
    Sponsor Name:Eli Lilly and Company Limited
    Full Title: Comparison of the Effects of Teriparatide with those of Risendronate on Lumbar Spine Volumetric Bone Mineral Density in GLucocorticpid-Induced Osteoporosis in Men
    Medical condition: Males with glucocorticoid-induced osteoporosis
    Disease:
    Population Age: Adults, Elderly Gender: Male
    Trial protocol: DE (Completed) GR (Completed) ES (Completed) IT (Completed)
    Trial results: View results
    EudraCT Number: 2011-004418-40 Sponsor Protocol Number: H9H-MC-JBAL Start Date*: 2012-02-23
    Sponsor Name:Lilly S.A,
    Full Title: A Phase 2 Study of LY2157299 Monohydrate Monotherapy or LY2157299 Monohydrate plus Lomustine Therapy compared to Lomustine Monotherapy in Patients with Recurrent Glioblastoma
    Medical condition: Glioblastoma
    Disease: Version SOC Term Classification Code Term Level
    14.1 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10018336 Glioblastoma PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: ES (Completed) DE (Completed) BE (Completed) IT (Completed) PL (Completed) NL (Completed)
    Trial results: View results
    EudraCT Number: 2015-002649-69 Sponsor Protocol Number: I1F-EW-RHBZ Start Date*: 2015-12-09
    Sponsor Name:Eli Lilly and Company Limited
    Full Title: A 24-Week Multicenter, Randomized, Open-Label, Parallel Group Study Comparing the Efficacy and Safety of Ixekizumab to Fumaric Acid Esters and Methotrexate in Patients with Moderate-to-Severe Plaqu...
    Medical condition: Moderate-to-Severe Plaque Psoriasis
    Disease: Version SOC Term Classification Code Term Level
    18.0 100000004858 10071117 Plaque psoriasis LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DE (Completed)
    Trial results: View results
    EudraCT Number: 2017-002374-39 Sponsor Protocol Number: I8B-MC-ITSI Start Date*: 2017-12-27
    Sponsor Name:Lilly S.A.
    Full Title: Protocol I8B-MC-ITSI A Prospective, Randomized, Double-Blind, Crossover Comparison Evaluating Compatibility and Safety of LY900014 and Insulin Lispro with an External Continuous Subcutaneous Insuli...
    Medical condition: Diabetes Mellitus, Type 1
    Disease: Version SOC Term Classification Code Term Level
    20.0 10027433 - Metabolism and nutrition disorders 10012601 Diabetes mellitus PT
    Population Age: Adults Gender: Male, Female
    Trial protocol: ES (Completed)
    Trial results: View results
    EudraCT Number: 2008-000748-14 Sponsor Protocol Number: H6Q-MC-S042 Start Date*: 2008-05-30
    Sponsor Name:Eli Lilly and Company limited
    Full Title: An Open Label, Multicenter Phase 2 Study of Single-Agent Enzastaurin HCl in Previously Treated Waldenstrom’s Macroglobulinemia or Multiple Myeloma
    Medical condition: Waldenstrom’s Macroglobulinemia or Multiple Myeloma
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: FR (Completed)
    Trial results: View results
    EudraCT Number: 2006-002112-99 Sponsor Protocol Number: F1K-MC-EVDK Start Date*: 2006-09-26
    Sponsor Name:Eli Lilly & Company Limited
    Full Title: A Phase 2 Study to Evaluate Dose and Duration of Treatment of Drotrecogin Alfa (Activated) Using Serial Measurements of Protein C in Patients with Severe Sepsis and Multiple Organ Dysfunction
    Medical condition: severe sepsis
    Disease: Version SOC Term Classification Code Term Level
    8.1 10040047 Sepsis LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DE (Completed) BE (Completed) SE (Prematurely Ended) FR (Completed) FI (Completed) IT (Completed) GB (Completed) ES (Completed)
    Trial results: View results
    EudraCT Number: 2009-011739-11 Sponsor Protocol Number: H3E-EW-S128 Start Date*: 2009-08-04
    Sponsor Name:Eli Lilly and Company Limited
    Full Title: Phase 2 Study of Pemetrexed and Cisplatin as Induction, Followed by Pemetrexed and Cisplatin with Concurrent Thoracic Radiotherapy, in Patients with Unresectable Locally-Advanced Stage III, Non-Squ...
    Medical condition: Non-small Cell Lung Cancer
    Disease: Version SOC Term Classification Code Term Level
    9.1 10029520 Non-small cell lung cancer stage IIIA LLT
    9.1 10029521 Non-small cell lung cancer stage IIIB LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: FR (Completed) ES (Completed) IT (Completed) DE (Completed)
    Trial results: View results
    EudraCT Number: 2013-000622-55 Sponsor Protocol Number: I5S-MC-EFJE Start Date*: 2013-07-31
    Sponsor Name:Eli Lilly and Company
    Full Title: A Phase 2 Efficacy and Safety Dose-Ranging Study of LY3015014 in Patients with Primary Hypercholesterolemia
    Medical condition: Primary hypercholesterolaemia
    Disease: Version SOC Term Classification Code Term Level
    14.1 10027433 - Metabolism and nutrition disorders 10020603 Hypercholesterolaemia PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: CZ (Completed) NL (Completed) PL (Completed) DK (Completed)
    Trial results: View results
    EudraCT Number: 2005-000900-15 Sponsor Protocol Number: B7A-MC-MBCU Start Date*: 2005-08-19
    Sponsor Name:Eli Lilly and Company
    Full Title: The effect of Ruboxistaurin on Clinically Significant Macular Edema in Patients with Diabetes Mellitus, as assessed by Optical Coherence Tomography
    Medical condition: Diabetic Macular Edema (DME), is the most common cause of visual impairment in patients with diabetic retinopathy (DR). It is the accumulation of extracellular fluid in the retinal tissues of the m...
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: GB (Completed) DK (Completed) DE (Completed) ES (Completed) LT (Completed)
    Trial results: View results
    EudraCT Number: 2012-004866-16 Sponsor Protocol Number: I5E-MC-TSAT Start Date*: 2013-06-06
    Sponsor Name:Eli Lilly and Company
    Full Title: A Randomized, Double-Blind, Placebo-Controlled Parallel Study with an Open-Label Extension to Assess the Impact of Testosterone Solution on Total Testosterone, Sex Drive and Energy in Hypogonadal Men.
    Medical condition: Male hypogonadism
    Disease: Version SOC Term Classification Code Term Level
    14.1 10014698 - Endocrine disorders 10021011 Hypogonadism male PT
    Population Age: Adults, Elderly Gender: Male
    Trial protocol: DE (Completed) IT (Completed) GB (Completed) ES (Completed)
    Trial results: View results
    EudraCT Number: 2005-004630-41 Sponsor Protocol Number: H6Q-MC-JCBJ Start Date*: 2006-04-26
    Sponsor Name:Eli Lilly and Company
    Full Title: A Phase 3 Clinical Study to Investigate the Prevention of Relapse in Lymphoma Using Daily Enzastaurin
    Medical condition: high-risk diffuse large B-cell lymphoma (DLBCL )
    Disease: Version SOC Term Classification Code Term Level
    14.1 100000004851 10012819 Diffuse large B-cell lymphomas HLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: SE (Prematurely Ended) HU (Completed) ES (Prematurely Ended) DK (Prematurely Ended) BE (Prematurely Ended) PT (Prematurely Ended) DE (Prematurely Ended) GR (Prematurely Ended) IT (Completed) GB (Prematurely Ended) CZ (Prematurely Ended) FI (Prematurely Ended)
    Trial results: View results
    EudraCT Number: 2004-000167-95 Sponsor Protocol Number: Protocol F1J-MC-HMDI Start Date*: 2005-03-03
    Sponsor Name:Eli Lilly and Company Limited
    Full Title: Duloxetine Versus Placebo in the Prevention of Recurrence of Major Depressive Disorder
    Medical condition: Major Depressive Disorder
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: SE (Completed) IT (Completed) DE (Completed)
    Trial results: View results
    EudraCT Number: 2015-005156-94 Sponsor Protocol Number: I3Y-MC-JPCE Start Date*: 2016-06-15
    Sponsor Name:Eli Lilly and Company
    Full Title: Protocol I3Y-MC-JPCE A Phase 1b Study of Abemaciclib in Combination with Pembrolizumab for Patients with Stage IV Non-Small Cell Lung Cancer or Hormone Receptor Positive, HER2 Negative Breast Cancer
    Medical condition: Stage IV Non-Small Cell Lung Cancer or Hormone Receptor Positive, HER2 Negative Breast Cancer
    Disease: Version SOC Term Classification Code Term Level
    20.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10006202 Breast cancer stage IV PT
    20.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10025055 Lung cancer non-small cell stage IV LLT
    Population Age: Adults Gender: Male, Female
    Trial protocol: BE (Trial now transitioned) ES (Completed) FR (Completed) IT (Completed)
    Trial results: (No results available)
    Download Options:
    Number of Trials to download:
    Download Content:
    Download Format:
    Note, where multi-state trials are shown in search results, selecting "Full Trial details" will download full information for each of the member states/countries involved in the trial.
    «« First « Previous 12  13  14  15  16  17  18  19  20  Next» Last»»
    Query did not match any studies.
    For support, Contact us.
    The status and protocol content of GB trials is no longer updated since 1 January 2021. For the UK, as of 31 January 2021, EU Law applies only to the territory of Northern Ireland (NI) to the extent foreseen in the Protocol on Ireland/NI. Legal notice
    As of 31 January 2023, all EU/EEA initial clinical trial applications must be submitted through CTIS . Updated EudraCT trials information and information on PIP/Art 46 trials conducted exclusively in third countries continues to be submitted through EudraCT and published on this website.

    European Medicines Agency © 1995-Sat Apr 25 16:49:53 CEST 2026 | Domenico Scarlattilaan 6, 1083 HS Amsterdam, The Netherlands
    EMA HMA